SCHEMBL13069151

SCHEMBL13069151

CC(C)(C)OC(=O)N[C@@H](CCCC(=O)c1ccc(O)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
HSD17B3 P37058 7/20 0.44
JAK3 P52333 1/20 0.44
BTK Q06187 1/20 0.44
HRH2 P25021 3/20 0.43
HRH1 P35367 3/20 0.43
P2RY2 P41231 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14002928 0.84 HRH2 (0.43) CTSKALDH1A1MAPTJAK3BTK
SCHEMBL2585108 0.83 ALDH1A1 (0.56) CTSSCTSKALDH1A1MAPTJAK3
SCHEMBL3626360 0.83 ALDH1A1 (0.56) CTSSCTSKALDH1A1MAPTJAK3
SCHEMBL32665591 0.82 NPSR1 (0.53) ALDH1A1MAPT
SCHEMBL4510174 0.80 PPARG (0.58) CTSSCTSKALDH1A1MAPTJAK3
SCHEMBL4092761 0.80 CTSS (0.49) CTSSCTSKNPC1RAB9AALDH1A1
SCHEMBL4092754 0.80 CTSS (0.49) CTSSCTSKNPC1RAB9AALDH1A1
SCHEMBL4510182 0.80 PPARG (0.58) CTSSCTSKALDH1A1MAPTJAK3
SCHEMBL2581127 0.78 ALDH1A1 (0.41) CTSSCTSKALDH1A1MAPTJAK3
SCHEMBL9196011 0.77 CTSK (0.50) CTSSCTSKP2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401433-B1 AZOLE ACID DERIVATIVES, ALONE OR IN COMBINATION, FOR TREATING DIABETES AND DYSLIPIDEMIAS; AND FOR TREATING MALIGNANT DISEASES BRISTOL MYERS SQUIBB CO (US) 2010-11-10 EP disclosed
US-7452907-B2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2008-11-18 US disclosed